French Trial Tragedy: US FDA Launches Safety Probe Of FAAH Inhibitors
This article was originally published in SRA
Executive Summary
US regulators are conducting a safety probe of fatty acid amide hydrolase (FAAH) inhibitors being developed and studied in the US, following the clinical trial tragedy in France where one healthy volunteer testing a product in that class died and five other participants experienced severe adverse neurological events1.